purpose: to assess the effect of erythropoietin (epo) plus granulocyte-colony stimulating factor (g-csf) treatment on survival and leukemic transformation in myelodysplastic syndrome (mds).
compared with that in mds patients without autoimmune disorders, the leukemic transformation rate was not increased in the mds/aid but the median survival time was shorter in mds/aid patients.